Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2019, Article ID 6392763, 26 pages
https://doi.org/10.1155/2019/6392763
Review Article

The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis

Molecular Pharmacology and Pathology Program, Department of Pathology and Bosch Institute, Medical Foundation Building (K25), University of Sydney, Sydney, New South Wales 2006, Australia

Correspondence should be addressed to Michael L.-H. Huang; ua.ude.yendys@gnauh.leahcim, Shannon Chiang; ua.ude.yendys@gnaihc.nonnahs, and Des R. Richardson; ua.ude.yendys@nosdrahcir.d

Received 13 November 2018; Revised 18 January 2019; Accepted 11 February 2019; Published 7 April 2019

Guest Editor: Livia Hool

Copyright © 2019 Michael L.-H. Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Napier, P. Ponka, and D. R. Richardson, “Iron trafficking in the mitochondrion: novel pathways revealed by disease,” Blood, vol. 105, no. 5, pp. 1867–1874, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. L. Circu and T. Y. Aw, “Reactive oxygen species, cellular redox systems, and apoptosis,” Free Radical Biology and Medicine, vol. 48, no. 6, pp. 749–762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, no. 7113, pp. 787–795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. R. Chen and J. L. Zweier, “Cardiac mitochondria and reactive oxygen species generation,” Circulation Research, vol. 114, no. 3, pp. 524–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Finkel and N. J. Holbrook, “Oxidants, oxidative stress and the biology of ageing,” Nature, vol. 408, no. 6809, pp. 239–247, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. M. T. Islam, “Oxidative stress and mitochondrial dysfunction-linked neurodegenerative disorders,” Neurological Research, vol. 39, no. 1, pp. 73–82, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. M.-Y. Cha, D. K. Kim, and I. Mook-Jung, “The role of mitochondrial DNA mutation on neurodegenerative diseases,” Experimental and Molecular Medicine, vol. 47, no. 3, article e150, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Shakeri, A. Kheirollahi, and J. Davoodi, “Apaf-1: regulation and function in cell death,” Biochimie, vol. 135, pp. 111–125, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-W. Taanman, “The mitochondrial genome: structure, transcription, translation and replication,” Biochimica et Biophysica Acta - Bioenergetics, vol. 1410, no. 2, pp. 103–123, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Trifunovic, “Mitochondrial DNA and ageing,” Biochimica et Biophysica Acta, vol. 1757, no. 5-6, pp. 611–617, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Corral-Debrinski, T. Horton, M. T. Lott, J. M. Shoffner, M. Flint Beal, and D. C. Wallace, “Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age,” Nature Genetics, vol. 2, no. 4, pp. 324–329, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. J. V. Leonard and A. H. V. Schapira, “Mitochondrial respiratory chain disorders I: mitochondrial DNA defects,” The Lancet, vol. 355, no. 9200, pp. 299–304, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. N. C. MacGarvey, H. B. Suliman, R. R. Bartz et al., “Activation of mitochondrial biogenesis by heme oxygenase-1-mediated NF-E2-related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 8, pp. 851–861, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Piantadosi, M. S. Carraway, A. Babiker, and H. B. Suliman, “Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1,” Circulation Research, vol. 103, no. 11, pp. 1232–1240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Itoh, T. Chiba, S. Takahashi et al., “An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313–322, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Dhakshinamoorthy and A. K. Jaiswal, “Small maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H:Quinone oxidoreductase1 gene,” Journal of Biological Chemistry, vol. 275, no. 51, pp. 40134–40141, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. L. E. Tebay, H. Robertson, S. T. Durant et al., “Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease,” Free Radical Biology and Medicine, vol. 88, Part B, pp. 108–146, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Rada, A. I. Rojo, N. Evrard-Todeschi et al., “Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/β-TrCP axis,” Molecular and Cellular Biology, vol. 32, no. 17, pp. 3486–3499, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Chowdhry, Y. Zhang, M. McMahon, C. Sutherland, A. Cuadrado, and J. D. Hayes, “Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity,” Oncogene, vol. 32, no. 32, pp. 3765–3781, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. W. Kaspar and A. K. Jaiswal, “Tyrosine phosphorylation controls nuclear export of Fyn, allowing Nrf2 activation of cytoprotective gene expression,” The FASEB Journal, vol. 25, no. 3, pp. 1076–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. K. Jain and A. K. Jaiswal, “GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2,” Journal of Biological Chemistry, vol. 282, no. 22, pp. 16502–16510, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Taguchi, N. Fujikawa, M. Komatsu et al., “Keap1 degradation by autophagy for the maintenance of redox homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 34, pp. 13561–13566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Jain, T. Lamark, E. Sjøttem et al., “p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription,” Journal of Biological Chemistry, vol. 285, no. 29, pp. 22576–22591, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Lau, X.-J. Wang, F. Zhao et al., “A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62,” Molecular and Cellular Biology, vol. 30, no. 13, pp. 3275–3285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Komatsu, H. Kurokawa, S. Waguri et al., “The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1,” Nature Cell Biology, vol. 12, no. 3, pp. 213–223, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Ichimura, S. Waguri, Y. S. Sou et al., “Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy,” Molecular Cell, vol. 51, no. 5, pp. 618–631, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. H. B. Suliman, M. S. Carraway, L. G. Tatro, and C. A. Piantadosi, “A new activating role for CO in cardiac mitochondrial biogenesis,” Journal of Cell Science, vol. 120, no. 2, pp. 299–308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. M. Holmstrom, L. Baird, Y. Zhang et al., “Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration,” Biology Open, vol. 2, no. 8, pp. 761–770, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. G. B. O'Mealey, K. S. Plafker, W. L. Berry, R. Janknecht, J. Y. Chan, and S. M. Plafker, “A PGAM5-KEAP1-Nrf2 complex is required for stress-induced mitochondrial retrograde trafficking,” Journal of Cell Science, vol. 130, no. 20, pp. 3467–3480, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. S. C. Lo and M. Hannink, “PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria,” Experimental Cell Research, vol. 314, no. 8, pp. 1789–1803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. S. C. Lo and M. Hannink, “PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex,” Journal of Biological Chemistry, vol. 281, no. 49, pp. 37893–37903, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Yang, X. Liu, F. Yang et al., “Mitochondrial phosphatase PGAM5 regulates Keap1-mediated Bcl-xL degradation and controls cardiomyocyte apoptosis driven by myocardial ischemia/reperfusion injury,” In Vitro Cellular & Developmental Biology - Animal, vol. 53, no. 3, pp. 248–257, 2017. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Bereiter-Hahn, “Chapter four - mitochondrial dynamics in aging and disease,” in The Mitochondrion in Aging and Disease, vol. 127 of Progress in Molecular Biology and Translational Science, pp. 93–131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Esteras, A. T. Dinkova-Kostova, and A. Y. Abramov, “Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function,” Biological Chemistry, vol. 397, no. 5, pp. 383–400, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Kubben, W. Zhang, L. Wang et al., “Repression of the antioxidant NRF2 pathway in premature aging,” Cell, vol. 165, no. 6, pp. 1361–1374, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Frank, “Dysregulation of mitochondrial fusion and fission: an emerging concept in neurodegeneration,” Acta Neuropathologica, vol. 111, no. 2, pp. 93–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Ikeda, S. Sciarretta, N. Nagarajan et al., “New insights into the role of mitochondrial dynamics and autophagy during oxidative stress and aging in the heart,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 210934, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Chen, Y. Liu, and G. W. Dorn II, “Mitochondrial fusion is essential for organelle function and cardiac homeostasis,” Circulation Research, vol. 109, no. 12, pp. 1327–1331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. R. J. Youle and A. M. van der Bliek, “Mitochondrial fission, fusion, and stress,” Science, vol. 337, no. 6098, pp. 1062–1065, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. L. Meeusen and J. Nunnari, “How mitochondria fuse,” Current Opinion in Cell Biology, vol. 17, no. 4, pp. 389–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Cipolat, O. M. de Brito, B. Dal Zilio, and L. Scorrano, “OPA1 requires mitofusin 1 to promote mitochondrial fusion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 45, pp. 15927–15932, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. O. M. de Brito and L. Scorrano, “Mitofusin 2: a mitochondria-shaping protein with signaling roles beyond fusion,” Antioxidants & Redox Signaling, vol. 10, no. 3, pp. 621–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Smirnova, L. Griparic, D. L. Shurland, and A. M. van der Bliek, “Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells,” Molecular Biology of the Cell, vol. 12, no. 8, pp. 2245–2256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. J. J. Lemasters, “Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging,” Rejuvenation Research, vol. 8, no. 1, pp. 3–5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. L. A. Scarffe, D. A. Stevens, V. L. Dawson, and T. M. Dawson, “Parkin and PINK1: much more than mitophagy,” Trends in Neurosciences, vol. 37, no. 6, pp. 315–324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Narendra, A. Tanaka, D. F. Suen, and R. J. Youle, “Parkin is recruited selectively to impaired mitochondria and promotes their autophagy,” The Journal of Cell Biology, vol. 183, no. 5, pp. 795–803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al., “Hereditary early-onset Parkinson’s disease caused by mutations in PINK1,” Science, vol. 304, no. 5674, pp. 1158–1160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Tanaka, M. M. Cleland, S. Xu et al., “Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin,” The Journal of Cell Biology, vol. 191, no. 7, pp. 1367–1380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Lazarou, D. A. Sliter, L. A. Kane et al., “The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy,” Nature, vol. 524, no. 7565, pp. 309–314, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Kondapalli, A. Kazlauskaite, N. Zhang et al., “PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating serine 65,” Open Biology, vol. 2, no. 5, article 120080, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Wauer, K. N. Swatek, J. L. Wagstaff et al., “Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis,” The EMBO Journal, vol. 34, no. 3, pp. 307–325, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Ziviani, R. N. Tao, and A. J. Whitworth, “Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 11, pp. 5018–5023, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. T. G. McWilliams, A. R. Prescott, L. Montava-Garriga et al., “Basal mitophagy occurs independently of PINK1 in mouse tissues of high metabolic demand,” Cell Metabolism, vol. 27, no. 2, pp. 439–449.e5, 2018. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Lazarou, “Keeping the immune system in check: a role for mitophagy,” Immunology and Cell Biology, vol. 93, no. 1, pp. 3–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. I. Novak, V. Kirkin, D. G. McEwan et al., “Nix is a selective autophagy receptor for mitochondrial clearance,” EMBO Reports, vol. 11, no. 1, pp. 45–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Liu, D. Feng, G. Chen et al., “Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells,” Nature Cell Biology, vol. 14, no. 2, pp. 177–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Di Rita, A. Peschiaroli, P. D’Acunzo et al., “HUWE1 E3 ligase promotes PINK1/PARKIN-independent mitophagy by regulating AMBRA1 activation via IKKα,” Nature Communications, vol. 9, no. 1, article 3755, p. 3755, 2018. View at Publisher · View at Google Scholar · View at Scopus
  58. I. Manoli, S. Alesci, M. R. Blackman, Y. A. Su, O. M. Rennert, and G. P. Chrousos, “Mitochondria as key components of the stress response,” Trends in Endocrinology and Metabolism, vol. 18, no. 5, pp. 190–198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Qadri, M. Namdeo, M. Behari, V. Goyal, S. Sharma, and A. K. Mukhopadhyay, “Alterations in mitochondrial membrane potential in peripheral blood mononuclear cells in Parkinson’s disease: potential for a novel biomarker,” Restorative Neurology and Neuroscience, vol. 36, no. 6, pp. 719–727, 2018. View at Publisher · View at Google Scholar
  60. V. Borutaite, “Mitochondria as decision-makers in cell death,” Environmental and Molecular Mutagenesis, vol. 51, no. 5, pp. 406–416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Ulukaya, C. Acilan, and Y. Yilmaz, “Apoptosis: why and how does it occur in biology?” Cell Biochemistry and Function, vol. 29, no. 6, pp. 468–480, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. H. A. Kalpage, V. Bazylianska, M. A. Recanati et al., “Tissue-specific regulation of cytochrome c by post-translational modifications: respiration, the mitochondrial membrane potential, ROS, and apoptosis,” The FASEB Journal, vol. 33, no. 2, pp. 1540–1553, 2019. View at Publisher · View at Google Scholar
  63. S. Yuan, M. Topf, T. F. Reubold, S. Eschenburg, and C. W. Akey, “Changes in Apaf-1 conformation that drive apoptosome assembly,” Biochemistry, vol. 52, no. 13, pp. 2319–2327, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Enari, H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, and S. Nagata, “A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD,” Nature, vol. 391, no. 6662, pp. 43–50, 1998. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Gonzalvez and E. Gottlieb, “Cardiolipin: setting the beat of apoptosis,” Apoptosis, vol. 12, no. 5, pp. 877–885, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. G. O. Fruhwirth and A. Hermetter, “Mediation of apoptosis by oxidized phospholipids,” Sub-Cellular Biochemistry, vol. 49, pp. 351–367, 2008. View at Publisher · View at Google Scholar
  68. S. Lucken-Ardjomande, S. Montessuit, and J. C. Martinou, “Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane,” Cell Death and Differentiation, vol. 15, no. 5, pp. 929–937, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. A. P. G. Dingeldein, T. Sparrman, and G. Grobner, “Oxidatively stressed mitochondria-mimicking membranes: a molecular insight into their organization during apoptosis,” Biochimica et Biophysica Acta, Biomembranes, vol. 1860, no. 12, pp. 2644–2654, 2018. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Ott, J. D. Robertson, V. Gogvadze, B. Zhivotovsky, and S. Orrenius, “Cytochrome c release from mitochondria proceeds by a two-step process,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1259–1263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. P. Santambrogio, G. Biasiotto, F. Sanvito, S. Olivieri, P. Arosio, and S. Levi, “Mitochondrial ferritin expression in adult mouse tissues,” The Journal of Histochemistry and Cytochemistry, vol. 55, no. 11, pp. 1129–1137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Petrosillo, F. M. Ruggiero, M. Pistolese, and G. Paradies, “Reactive oxygen species generated from the mitochondrial electron transport chain induce cytochrome c dissociation from beef-heart submitochondrial particles via cardiolipin peroxidation. Possible role in the apoptosis,” FEBS Letters, vol. 509, no. 3, pp. 435–438, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. H. K. Lorenzo and S. A. Susin, “Mitochondrial effectors in caspase-independent cell death,” FEBS Letters, vol. 557, no. 1-3, pp. 14–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Ye, C. Cande, N. C. Stephanou et al., “DNA binding is required for the apoptogenic action of apoptosis inducing factor,” Nature Structural Biology, vol. 9, no. 9, pp. 680–684, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Yang, W. Han, Y. Luo et al., “Adapentpronitrile, a new dipeptidyl peptidase-IV inhibitor, ameliorates diabetic neuronal injury through inhibiting mitochondria-related oxidative stress and apoptosis,” Frontiers in Cellular Neuroscience, vol. 12, p. 214, 2018. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Martín-Fernández and R. Gredilla, “Mitochondrial oxidative stress and cardiac ageing,” Clínica e Investigación en Arteriosclerosis (English Edition), vol. 30, no. 2, pp. 74–83, 2018. View at Publisher · View at Google Scholar
  77. J. D. Marshall, I. Bazan, Y. Zhang, W. H. Fares, and P. J. Lee, “Mitochondrial dysfunction and pulmonary hypertension: cause, effect, or both,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 314, no. 5, pp. L782–l796, 2018. View at Publisher · View at Google Scholar
  78. D. R. Richardson and P. Ponka, “The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells,” Biochimica et Biophysica Acta, vol. 1331, no. 1, pp. 1–40, 1997. View at Publisher · View at Google Scholar · View at Scopus
  79. G. C. Shaw, J. J. Cope, L. Li et al., “Mitoferrin is essential for erythroid iron assimilation,” Nature, vol. 440, no. 7080, pp. 96–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Foury and T. Roganti, “Deletion of the mitochondrial carrier genes MRS3 and MRS4 suppresses mitochondrial iron accumulation in a yeast frataxin-deficient strain,” Journal of Biological Chemistry, vol. 277, no. 27, pp. 24475–24483, 2002. View at Publisher · View at Google Scholar · View at Scopus
  81. U. Mühlenhoff, J. A. Stadler, N. Richhardt et al., “A specific role of the yeast mitochondrial carriers Mrs3/4p in mitochondrial iron acquisition under iron-limiting conditions,” Journal of Biological Chemistry, vol. 278, no. 42, pp. 40612–40620, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. U. Mühlenhoff, S. Molik, J. R. Godoy et al., “Cytosolic monothiol glutaredoxins function in intracellular iron sensing and trafficking via their bound iron-sulfur cluster,” Cell Metabolism, vol. 12, no. 4, pp. 373–385, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. C. C. Philpott, “Coming into view: eukaryotic iron chaperones and intracellular iron delivery,” Journal of Biological Chemistry, vol. 287, no. 17, pp. 13518–13523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Shvartsman and Z. Ioav Cabantchik, “Intracellular iron trafficking: role of cytosolic ligands,” Biometals, vol. 25, no. 4, pp. 711–723, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. A. D. Sheftel, A. S. Zhang, C. Brown, O. S. Shirihai, and P. Ponka, “Direct interorganellar transfer of iron from endosome to mitochondrion,” Blood, vol. 110, no. 1, pp. 125–132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  86. W. Chen, P. N. Paradkar, L. Li et al., “Abcb10 physically interacts with mitoferrin-1 (Slc25a37) to enhance its stability and function in the erythroid mitochondria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 38, pp. 16263–16268, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Engl and D. Attwell, “Non-signalling energy use in the brain,” Journal of Physiology, vol. 593, no. 16, pp. 3417–3429, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Okouchi, O. Ekshyyan, M. Maracine, and T. Y. Aw, “Neuronal apoptosis in neurodegeneration,” Antioxidants & Redox Signaling, vol. 9, no. 8, pp. 1059–1096, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Prince, A. Wimo, M. Guerchet, G. Ali, Y. Wu, and M. Prina, World Alzheimer Report 2015: The Global Impact of Dementia: an Analysis of Prevalence, Incidence, Cost and Trends, 2015, Google Scholar.
  90. H. K. Anandatheerthavarada, G. Biswas, M. A. Robin, and N. G. Avadhani, “Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells,” The Journal of Cell Biology, vol. 161, no. 1, pp. 41–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Ankarcrona and K. Hultenby, “Presenilin-1 is located in rat mitochondria,” Biochemical and Biophysical Research Communications, vol. 295, no. 3, pp. 766–770, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. C. A. Hansson, S. Frykman, M. R. Farmery et al., “Nicastrin, presenilin, APH-1, and PEN-2 form active γ-secretase complexes in mitochondria,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51654–51660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. J. W. Lustbader, M. Cirilli, C. Lin et al., “ABAD directly links Aß to mitochondrial toxicity in Alzheimer’s disease,” Science, vol. 304, no. 5669, pp. 448–452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Du, L. Guo, F. Fang et al., “Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease,” Nature Medicine, vol. 14, no. 10, pp. 1097–1105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. R. H. Swerdlow, J. K. Parks, D. S. Cassarino et al., “Cybrids in Alzheimer’s disease: a cellular model of the disease?” Neurology, vol. 49, no. 4, pp. 918–925, 1997. View at Publisher · View at Google Scholar · View at Scopus
  96. P. E. Coskun, M. F. Beal, and D. C. Wallace, “Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10726–10731, 2004. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. Zou, B. Hong, L. Fan et al., “Protective effect of puerarin against beta-amyloid-induced oxidative stress in neuronal cultures from rat hippocampus: involvement of the GSK-3β/Nrf2 signaling pathway,” Free Radical Research, vol. 47, no. 1, pp. 55–63, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Jiao, F. Gao, L. Ou et al., “Tetrahydroxy stilbene glycoside (TSG) antagonizes Aβ-induced hippocampal neuron injury by suppressing mitochondrial dysfunction via Nrf2-dependent HO-1 pathway,” Biomedicine & Pharmacotherapy, vol. 96, pp. 222–228, 2017. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Cuadrado, S. Kugler, and I. Lastres-Becker, “Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy,” Redox Biology, vol. 14, pp. 522–534, 2018. View at Publisher · View at Google Scholar · View at Scopus
  100. C. D. SanMartin, T. Adasme, C. Hidalgo, and A. C. Paula-Lima, “The antioxidant N-acetylcysteine prevents the mitochondrial fragmentation induced by soluble amyloid-F peptide oligomers,” Neurodegenerative Diseases, vol. 10, no. 1-4, pp. 34–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. X. Wang, B. Su, S. L. Siedlak et al., “Amyloid-β overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 49, pp. 19318–19323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Manczak, M. J. Calkins, and P. H. Reddy, “Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage,” Human Molecular Genetics, vol. 20, no. 13, pp. 2495–2509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Manczak, R. Kandimalla, D. Fry, H. Sesaki, and P. H. Reddy, “Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease,” Human Molecular Genetics, vol. 25, no. 23, pp. 5148–5166, 2016. View at Publisher · View at Google Scholar · View at Scopus
  104. S. H. Baek, S. J. Park, J. I. Jeong et al., “Inhibition of Drp1 ameliorates synaptic depression, Aβ deposition, and cognitive impairment in an Alzheimer’s disease model,” Journal of Neuroscience, vol. 37, no. 20, pp. 5099–5110, 2017. View at Publisher · View at Google Scholar · View at Scopus
  105. P. H. Reddy, M. Manczak, and X. L. Yin, “Mitochondria-division inhibitor 1 protects against amyloid-β induced mitochondrial fragmentation and synaptic damage in Alzheimer’s disease,” Journal of Alzheimer's Disease, vol. 58, no. 1, pp. 147–162, 2017. View at Publisher · View at Google Scholar · View at Scopus
  106. R. D. Terry, E. Masliah, D. P. Salmon et al., “Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment,” Annals of Neurology, vol. 30, no. 4, pp. 572–580, 1991. View at Publisher · View at Google Scholar · View at Scopus
  107. S. T. DeKosky and S. W. Scheff, “Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity,” Annals of Neurology, vol. 27, no. 5, pp. 457–464, 1990. View at Publisher · View at Google Scholar · View at Scopus
  108. E. K. Pickett, J. Rose, C. McCrory et al., “Region-specific depletion of synaptic mitochondria in the brains of patients with Alzheimer’s disease,” Acta Neuropathologica, vol. 136, no. 5, pp. 747–757, 2018. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Drubin, S. Kobayashi, and M. Kirschner, “Association of tau protein with microtubules in living cells,” Annals of the New York Academy of Sciences, vol. 466, 1 Dynamic Aspec, pp. 257–268, 1986. View at Publisher · View at Google Scholar · View at Scopus
  110. K. J. Kopeikina, G. A. Carlson, R. Pitstick et al., “Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain,” The American Journal of Pathology, vol. 179, no. 4, pp. 2071–2082, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. W. Stoothoff, P. B. Jones, T. L. Spires-Jones et al., “Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport,” Journal of Neurochemistry, vol. 111, no. 2, pp. 417–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. M. J. Calkins and P. H. Reddy, “Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1812, no. 4, pp. 507–513, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. H. Decker, K. Y. Lo, S. M. Unger, S. T. Ferreira, and M. A. Silverman, “Amyloid-β peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by glycogen synthase kinase 3β in primary cultured hippocampal neurons,” Journal of Neuroscience, vol. 30, no. 27, pp. 9166–9171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. Y. Rui and J. Q. Zheng, “Amyloid β oligomers elicit mitochondrial transport defects and fragmentation in a time-dependent and pathway-specific manner,” Molecular Brain, vol. 9, no. 1, p. 79, 2016. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Wang, M. Wang, J. Hu et al., “Protective effect of 3H-1, 2-dithiole-3-thione on cellular model of Alzheimer’s disease involves Nrf2/ARE signaling pathway,” European Journal of Pharmacology, vol. 795, pp. 115–123, 2017. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Busciglio, A. Pelsman, C. Wong et al., “Altered metabolism of the amyloid β precursor protein is associated with mitochondrial dysfunction in Down’s syndrome,” Neuron, vol. 33, no. 5, pp. 677–688, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. E. Alberdi, M. V. Sánchez-Gómez, A. Ruiz et al., “Mangiferin and morin attenuate oxidative stress, mitochondrial dysfunction, and neurocytotoxicity, induced by amyloid beta oligomers,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 2856063, 13 pages, 2018. View at Publisher · View at Google Scholar · View at Scopus
  118. A. B. Reiss, H. A. Arain, M. M. Stecker, N. M. Siegart, and L. J. Kasselman, “Amyloid toxicity in Alzheimer’s disease,” Reviews in the Neurosciences, vol. 29, no. 6, pp. 613–627, 2018. View at Publisher · View at Google Scholar · View at Scopus
  119. M. G. Bartley, K. Marquardt, D. Kirchhof, H. M. Wilkins, D. Patterson, and D. A. Linseman, “Overexpression of amyloid-β protein precursor induces mitochondrial oxidative stress and activates the intrinsic apoptotic cascade,” Journal of Alzheimer's Disease, vol. 28, no. 4, pp. 855–868, 2012. View at Publisher · View at Google Scholar · View at Scopus
  120. B. Ding, K. M. Chen, H. W. Ling et al., “Correlation of iron in the hippocampus with MMSE in patients with Alzheimer’s disease,” Journal of Magnetic Resonance Imaging, vol. 29, no. 4, pp. 793–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. M. A. Smith, P. L. R. Harris, L. M. Sayre, and G. Perry, “Iron accumulation in Alzheimer disease is a source of redox-generated free radicals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 18, pp. 9866–9868, 1997. View at Publisher · View at Google Scholar · View at Scopus
  122. A. A. Belaidi and A. I. Bush, “Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics,” Journal of Neurochemistry, vol. 139, Supplement 1, pp. 179–197, 2016. View at Publisher · View at Google Scholar · View at Scopus
  123. W. Zheng, N. Xin, Z. H. Chi et al., “Divalent metal transporter 1 is involved in amyloid precursor protein processing and Aβ generation,” The FASEB Journal, vol. 23, no. 12, pp. 4207–4217, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. J. R. Connor, S. L. Menzies, S. M. St Martin, and E. J. Mufson, “A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains,” Journal of Neuroscience Research, vol. 31, no. 1, pp. 75–83, 1992. View at Publisher · View at Google Scholar · View at Scopus
  125. A. A. Raha, R. A. Vaishnav, R. P. Friedland, A. Bomford, and R. Raha-Chowdhury, “The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease,” Acta Neuropathologica Communications, vol. 1, no. 1, p. 55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. J. T. Rogers, J. D. Randall, C. M. Cahill et al., “An iron-responsive element type II in the 5-untranslated region of the Alzheimer’s amyloid precursor protein transcript,” Journal of Biological Chemistry, vol. 277, no. 47, pp. 45518–45528, 2002. View at Publisher · View at Google Scholar · View at Scopus
  127. J. Huang, S. Chen, L. Hu et al., “Mitoferrin-1 is involved in the progression of Alzheimer’s disease through targeting mitochondrial iron metabolism in a Caenorhabditis elegans model of Alzheimer’s disease,” Neuroscience, vol. 385, pp. 90–101, 2018. View at Publisher · View at Google Scholar · View at Scopus
  128. W. S. Wu, Y. S. Zhao, Z. H. Shi et al., “Mitochondrial ferritin attenuates β-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways,” Antioxidants & Redox Signaling, vol. 18, no. 2, pp. 158–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. P. Wang, Q. Wu, W. Wu et al., “Mitochondrial ferritin deletion exacerbates β-amyloid-induced neurotoxicity in mice,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 1020357, 10 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  130. L. M. de Lau and M. M. Breteler, “Epidemiology of Parkinson’s disease,” The Lancet Neurology, vol. 5, no. 6, pp. 525–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. O.-B. Tysnes and A. Storstein, “Epidemiology of Parkinson’s disease,” Journal of Neural Transmission, vol. 124, no. 8, pp. 901–905, 2017. View at Publisher · View at Google Scholar · View at Scopus
  132. L. A. Bindoff, M. Birch-Machin, N. E. F. Cartlidge, W. D. Parker JR, and D. M. Turnbull, “Mitochondrial function in Parkinson’s disease,” The Lancet, vol. 334, no. 8653, p. 49, 1989. View at Publisher · View at Google Scholar · View at Scopus
  133. A. H. V. Schapira, J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. D. Marsden, “Mitochondrial complex I deficiency in Parkinson’s disease,” The Lancet, vol. 333, no. 8649, p. 1269, 1989. View at Publisher · View at Google Scholar · View at Scopus
  134. A. H. V. Schapira, V. M. Mann, J. M. Cooper et al., “Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease,” Journal of Neurochemistry, vol. 55, no. 6, pp. 2142–2145, 1990. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Grünewald, K. A. Rygiel, P. D. Hepplewhite, C. M. Morris, M. Picard, and D. M. Turnbull, “Mitochondrial DNA depletion in respiratory chain–deficient Parkinson disease neurons,” Annals of Neurology, vol. 79, no. 3, pp. 366–378, 2016. View at Publisher · View at Google Scholar · View at Scopus
  136. A. Grünewald, K. R. Kumar, and C. M. Sue, “New insights into the complex role of mitochondria in Parkinson’s disease,” Progress in Neurobiology, 2018. View at Publisher · View at Google Scholar
  137. A. Iwai, E. Masliah, M. Yoshimoto et al., “The precursor protein of non-Aβ component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system,” Neuron, vol. 14, no. 2, pp. 467–475, 1995. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Burré, “The synaptic function of α-synuclein,” Journal of Parkinson's Disease, vol. 5, no. 4, pp. 699–713, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. N. Hattori, H. Kobayashi, Y. Sasaki-Hatano, K. Sato, and Y. Mizuno, “Familial Parkinson’s disease: a hint to elucidate the mechanisms of nigral degeneration,” Journal of Neurology, vol. 250, Supplement 3, pp. iii2–iii10, 2003. View at Publisher · View at Google Scholar
  140. J. Xu, S. Y. Kao, F. J. S. Lee, W. Song, L. W. Jin, and B. A. Yankner, “Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease,” Nature Medicine, vol. 8, no. 6, pp. 600–606, 2002. View at Publisher · View at Google Scholar · View at Scopus
  141. D. E. Mor, E. Tsika, J. R. Mazzulli et al., “Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration,” Nature Neuroscience, vol. 20, no. 11, pp. 1560–1568, 2017. View at Publisher · View at Google Scholar · View at Scopus
  142. A. E. Budson and P. R. Solomon, “Chapter 5 - dementia with Lewy bodies (including Parkinson’s disease dementia),” in Memory Loss, Alzheimer's Disease, and Dementia (Second Edition): A Practical Guide for Clinicians, A. E. Budson and P. R. Solomon, Eds., pp. 70–79, Elsevier, London, 2016. View at Publisher · View at Google Scholar
  143. W.-W. Li, R. Yang, J.-C. Guo et al., “Localization of α-synuclein to mitochondria within midbrain of mice,” Neuroreport, vol. 18, no. 15, pp. 1543–1546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. A. K. Reeve, M. H. R. Ludtmann, P. R. Angelova et al., “Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons,” Cell Death & Disease, vol. 6, no. 7, article e1820, 2015. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Devi, V. Raghavendran, B. M. Prabhu, N. G. Avadhani, and H. K. Anandatheerthavarada, “Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain,” Journal of Biological Chemistry, vol. 283, no. 14, pp. 9089–9100, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. D. D. Song, C. W. Shults, A. Sisk, E. Rockenstein, and E. Masliah, “Enhanced substantia nigra mitochondrial pathology in human α-synuclein transgenic mice after treatment with MPTP,” Experimental Neurology, vol. 186, no. 2, pp. 158–172, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. F. Fornai, O. M. Schluter, P. Lenzi et al., “Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and α-synuclein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3413–3418, 2005. View at Publisher · View at Google Scholar · View at Scopus
  148. P. Klivenyi, D. Siwek, G. Gardian et al., “Mice lacking alpha-synuclein are resistant to mitochondrial toxins,” Neurobiology of Disease, vol. 21, no. 3, pp. 541–548, 2006. View at Publisher · View at Google Scholar · View at Scopus
  149. R. Di Maio, P. J. Barrett, E. K. Hoffman et al., “α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease,” Science Translational Medicine, vol. 8, no. 342, article 342ra78, 2016. View at Publisher · View at Google Scholar · View at Scopus
  150. T. K. Rostovtseva, P. A. Gurnev, O. Protchenko et al., “α-Synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease,” Journal of Biological Chemistry, vol. 290, no. 30, pp. 18467–18477, 2015. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Paillusson, P. Gomez-Suaga, R. Stoica et al., “α-Synuclein binds to the ER–mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production,” Acta Neuropathologica, vol. 134, no. 1, pp. 129–149, 2017. View at Publisher · View at Google Scholar · View at Scopus
  152. C. Guardia-Laguarta, E. Area-Gomez, C. Rub et al., “α-Synuclein is localized to mitochondria-associated ER membranes,” Journal of Neuroscience, vol. 34, no. 1, pp. 249–259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  153. M. H. R. Ludtmann, P. R. Angelova, N. N. Ninkina, S. Gandhi, V. L. Buchman, and A. Y. Abramov, “Monomeric alpha-synuclein exerts a physiological role on brain ATP synthase,” Journal of Neuroscience, vol. 36, no. 41, pp. 10510–10521, 2016. View at Publisher · View at Google Scholar · View at Scopus
  154. M. H. R. Ludtmann, P. R. Angelova, M. H. Horrocks et al., “α-Synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson’s disease,” Nature Communications, vol. 9, no. 1, article 2293, 2018. View at Publisher · View at Google Scholar · View at Scopus
  155. F. Kamp, N. Exner, A. K. Lutz et al., “Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1,” The EMBO Journal, vol. 29, no. 20, pp. 3571–3589, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. L. Chen, Z. Xie, S. Turkson, and X. Zhuang, “A53T human α-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration,” Journal of Neuroscience, vol. 35, no. 3, pp. 890–905, 2015. View at Publisher · View at Google Scholar · View at Scopus
  157. C. Y. Chung, V. Khurana, S. Yi et al., “In situ peroxidase labeling and mass-spectrometry connects alpha-synuclein directly to endocytic trafficking and mRNA metabolism in neurons,” Cell Systems, vol. 4, no. 2, pp. 242–250.e4, 2017. View at Publisher · View at Google Scholar · View at Scopus
  158. H. J. Lee, K. Lee, and H. Im, “α-Synuclein modulates neurite outgrowth by interacting with SPTBN1,” Biochemical and Biophysical Research Communications, vol. 424, no. 3, pp. 497–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  159. D. G. Ordonez, M. K. Lee, and M. B. Feany, “α-Synuclein induces mitochondrial dysfunction through Spectrin and the actin cytoskeleton,” Neuron, vol. 97, no. 1, pp. 108–124.e6, 2018. View at Publisher · View at Google Scholar · View at Scopus
  160. D. Grassi, S. Howard, M. Zhou et al., “Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson’s disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 11, pp. E2634–e2643, 2018. View at Publisher · View at Google Scholar · View at Scopus
  161. D. P. Narendra, S. M. Jin, A. Tanaka et al., “PINK1 is selectively stabilized on impaired mitochondria to activate Parkin,” PLoS Biology, vol. 8, no. 1, article e1000298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. A. Petit, T. Kawarai, E. Paitel et al., “Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations,” Journal of Biological Chemistry, vol. 280, no. 40, pp. 34025–34032, 2005. View at Publisher · View at Google Scholar · View at Scopus
  163. A. M. Todd and B. E. Staveley, “Expression of Pink1 with α-synuclein in the dopaminergic neurons of Drosophila leads to increases in both lifespan and healthspan,” Genetics and Molecular Research, vol. 11, no. 2, pp. 1497–1502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  164. J. Liu, X. Wang, Y. Lu et al., “Pink1 interacts with α-synuclein and abrogates α-synuclein-induced neurotoxicity by activating autophagy,” Cell Death & Disease, vol. 8, no. 9, article e3056, 2017. View at Publisher · View at Google Scholar · View at Scopus
  165. M. Oliveras-Salvá, F. Macchi, V. Coessens et al., “Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice,” Neurobiology of Aging, vol. 35, no. 11, pp. 2625–2636, 2014. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Gispert, N. Brehm, J. Weil et al., “Potentiation of neurotoxicity in double-mutant mice with Pink1 ablation and A53T-SNCA overexpression,” Human Molecular Genetics, vol. 24, no. 4, pp. 1061–1076, 2015. View at Publisher · View at Google Scholar · View at Scopus
  167. V. Bonifati, P. Rizzu, M. van Baren et al., “Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism,” Science, vol. 299, no. 5604, pp. 256–259, 2003. View at Publisher · View at Google Scholar · View at Scopus
  168. E. Andres-Mateos, C. Perier, L. Zhang et al., “DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 37, pp. 14807–14812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  169. J. N. Guzman, J. Sanchez-Padilla, D. Wokosin et al., “Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1,” Nature, vol. 468, no. 7324, pp. 696–700, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. J. Y. Heo, J. H. Park, S. J. Kim et al., “DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly,” PLoS One, vol. 7, no. 3, article e32629, 2012. View at Publisher · View at Google Scholar · View at Scopus
  171. M. C. Meulener, C. L. Graves, D. M. Sampathu, C. E. Armstrong-Gold, N. M. Bonini, and B. I. Giasson, “DJ-1 is present in a large molecular complex in human brain tissue and interacts with α-synuclein,” Journal of Neurochemistry, vol. 93, no. 6, pp. 1524–1532, 2005. View at Publisher · View at Google Scholar · View at Scopus
  172. L. Zondler, L. Miller-Fleming, M. Repici et al., “DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson’s disease,” Cell Death & Disease, vol. 5, no. 7, article e1350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  173. D. J. Moore, L. Zhang, J. Troncoso et al., “Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress,” Human Molecular Genetics, vol. 14, no. 1, pp. 71–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. B. Tang, H. Xiong, P. Sun et al., “Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson’s disease,” Human Molecular Genetics, vol. 15, no. 11, pp. 1816–1825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  175. K. J. Thomas, M. K. McCoy, J. Blackinton et al., “DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy,” Human Molecular Genetics, vol. 20, no. 1, pp. 40–50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  176. G. Krebiehl, S. Ruckerbauer, L. F. Burbulla et al., “Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson’s disease-associated protein DJ-1,” PLoS One, vol. 5, no. 2, article e9367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. I. Irrcher, H. Aleyasin, E. L. Seifert et al., “Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics,” Human Molecular Genetics, vol. 19, no. 19, pp. 3734–3746, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. R. M. Canet-Avilés, M. A. Wilson, D. W. Miller et al., “The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 24, pp. 9103–9108, 2004. View at Publisher · View at Google Scholar · View at Scopus
  179. C. M. Clements, R. S. McNally, B. J. Conti, T. W. Mak, and J. P.-Y. Ting, “DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15091–15096, 2006. View at Publisher · View at Google Scholar · View at Scopus
  180. N. C. Burton, T. W. Kensler, and T. R. Guilarte, “In vivo modulation of the parkinsonian phenotype by Nrf2,” Neurotoxicology, vol. 27, no. 6, pp. 1094–1100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  181. P.-C. Chen, M. R. Vargas, A. K. Pani et al., “Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2933–2938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  182. A. Jazwa, A. I. Rojo, N. G. Innamorato, M. Hesse, J. Fernández-Ruiz, and A. Cuadrado, “Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism,” Antioxidants & Redox Signaling, vol. 14, no. 12, pp. 2347–2360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  183. M. von Otter, S. Landgren, S. Nilsson et al., “Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson’s disease,” BMC Medical Genetics, vol. 11, no. 1, p. 36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. A. T. Dinkova-Kostova, L. Baird, K. M. Holmström, C. J. Meyer, and A. Y. Abramov, “The spatiotemporal regulation of the Keap1–Nrf2 pathway and its importance in cellular bioenergetics,” Biochemical Society Transactions, vol. 43, no. 4, pp. 602–610, 2015. View at Publisher · View at Google Scholar · View at Scopus
  185. C. Paisán-Ruı́z, S. Jain, E. W. Evans et al., “Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease,” Neuron, vol. 44, no. 4, pp. 595–600, 2004. View at Publisher · View at Google Scholar · View at Scopus
  186. A. Zimprich, S. Biskup, P. Leitner et al., “Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology,” Neuron, vol. 44, no. 4, pp. 601–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  187. L. H. Sanders, J. Laganière, O. Cooper et al., “LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction,” Neurobiology of Disease, vol. 62, pp. 381–386, 2014. View at Publisher · View at Google Scholar · View at Scopus
  188. O. Cooper, H. Seo, S. Andrabi et al., “Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease,” Science Translational Medicine, vol. 4, no. 141, article 141ra90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  189. D. Santos, A. R. Esteves, D. F. Silva, C. Januário, and S. M. Cardoso, “The impact of mitochondrial fusion and fission modulation in sporadic Parkinson’s disease,” Molecular Neurobiology, vol. 52, no. 1, pp. 573–586, 2015. View at Publisher · View at Google Scholar · View at Scopus
  190. E. Greggio, S. Jain, A. Kingsbury et al., “Kinase activity is required for the toxic effects of mutant LRRK2/dardarin,” Neurobiology of Disease, vol. 23, no. 2, pp. 329–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  191. E. H. Howlett, N. Jensen, F. Belmonte et al., “LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease,” Human Molecular Genetics, vol. 26, no. 22, pp. 4340–4351, 2017. View at Publisher · View at Google Scholar · View at Scopus
  192. A. B. West, D. J. Moore, S. Biskup et al., “Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 46, pp. 16842–16847, 2005. View at Publisher · View at Google Scholar · View at Scopus
  193. X. Wang, M. H. Yan, H. Fujioka et al., “LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1,” Human Molecular Genetics, vol. 21, no. 9, pp. 1931–1944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  194. K. Stafa, E. Tsika, R. Moser et al., “Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin GTPase superfamily,” Human Molecular Genetics, vol. 23, no. 8, pp. 2055–2077, 2014. View at Publisher · View at Google Scholar · View at Scopus
  195. C. J. Gloeckner, N. Kinkl, A. Schumacher et al., “The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity,” Human Molecular Genetics, vol. 15, no. 2, pp. 223–232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  196. L. M. Martins, A. Morrison, K. Klupsch et al., “Neuroprotective role of the reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice,” Molecular and Cellular Biology, vol. 24, no. 22, pp. 9848–9862, 2004. View at Publisher · View at Google Scholar · View at Scopus
  197. K. M. Strauss, L. M. Martins, H. Plun-Favreau et al., “Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease,” Human Molecular Genetics, vol. 14, no. 15, pp. 2099–2111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  198. V. Bogaerts, K. Nuytemans, J. Reumers et al., “Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease,” Human Mutation, vol. 29, no. 6, pp. 832–840, 2008. View at Publisher · View at Google Scholar · View at Scopus
  199. R. K. Dagda and C. T. Chu, “Mitochondrial quality control: insights on how Parkinson’s disease related genes PINK1, parkin, and Omi/HtrA2 interact to maintain mitochondrial homeostasis,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 6, pp. 473–479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  200. K. Fu, Y. Wang, D. Guo, G. Wang, and H. Ren, “Familial Parkinson’s disease-associated L166P mutant DJ-1 is cleaved by mitochondrial serine protease Omi/HtrA2,” Neuroscience Bulletin, vol. 33, no. 6, pp. 685–694, 2017. View at Publisher · View at Google Scholar · View at Scopus
  201. Y. Yang, L. J. Xue, X. Xue, Z. Ou, T. Jiang, and Y. D. Zhang, “MFN2 ameliorates cell apoptosis in a cellular model of Parkinson’s disease induced by rotenone,” Experimental and Therapeutic Medicine, vol. 16, no. 4, pp. 3680–3685, 2018. View at Publisher · View at Google Scholar · View at Scopus
  202. Z. Ou, T. Jiang, Q. Gao et al., “Mitochondrial-dependent mechanisms are involved in angiotensin II-induced apoptosis in dopaminergic neurons,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 17, no. 4, 2016. View at Publisher · View at Google Scholar · View at Scopus
  203. M. C. Kiernan, S. Vucic, B. C. Cheah et al., “Amyotrophic lateral sclerosis,” The Lancet, vol. 377, no. 9769, pp. 942–955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  204. E. F. Smith, P. J. Shaw, and K. J. De Vos, “The role of mitochondria in amyotrophic lateral sclerosis,” Neuroscience Letters, 2017. View at Publisher · View at Google Scholar · View at Scopus
  205. D. R. Rosen, T. Siddique, D. Patterson et al., “Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis,” Nature, vol. 362, no. 6415, pp. 59–62, 1993. View at Publisher · View at Google Scholar · View at Scopus
  206. S. Sasaki and M. Iwata, “Mitochondrial alterations in the spinal cord of patients with sporadic amyotrophic lateral sclerosis,” Journal of Neuropathology & Experimental Neurology, vol. 66, no. 1, pp. 10–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  207. J. Magrané, C. Cortez, W.-B. Gan, and G. Manfredi, “Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models,” Human Molecular Genetics, vol. 23, no. 6, pp. 1413–1424, 2014. View at Publisher · View at Google Scholar · View at Scopus
  208. W. Wang, L. Li, W.-L. Lin et al., “The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons,” Human Molecular Genetics, vol. 22, no. 23, pp. 4706–4719, 2013. View at Publisher · View at Google Scholar · View at Scopus
  209. R. Dafinca, J. Scaber, N.a. Ababneh et al., “C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia,” Stem Cells, vol. 34, no. 8, pp. 2063–2078, 2016. View at Publisher · View at Google Scholar · View at Scopus
  210. E. Onesto, C. Colombrita, V. Gumina et al., “Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts,” Acta Neuropathologica Communications, vol. 4, no. 1, p. 47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  211. A. Ferri, P. Fiorenzo, M. Nencini et al., “Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity,” Human Molecular Genetics, vol. 19, no. 22, pp. 4529–4542, 2010. View at Publisher · View at Google Scholar · View at Scopus
  212. W. Liu, T. Yamashita, F. Tian et al., “Mitochondrial fusion and fission proteins expression dynamically change in a murine model of amyotrophic lateral sclerosis,” Current Neurovascular Research, vol. 10, no. 3, pp. 222–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  213. Y.-F. Xu, T. F. Gendron, Y.-J. Zhang et al., “Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice,” The Journal of Neuroscience, vol. 30, no. 32, pp. 10851–10859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  214. C. Stribl, A. Samara, D. Trümbach et al., “Mitochondrial dysfunction and decrease in body weight of a transgenic knock-in mouse model for TDP-43,” Journal of Biological Chemistry, vol. 289, no. 15, pp. 10769–10784, 2014. View at Publisher · View at Google Scholar · View at Scopus
  215. C. Vande Velde, K. K. McDonald, Y. Boukhedimi et al., “Misfolded SOD1 associated with motor neuron mitochondria alters mitochondrial shape and distribution prior to clinical onset,” PLoS One, vol. 6, no. 7, article e22031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  216. K. J. De Vos, A. L. Chapman, M. E. Tennant et al., “Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content,” Human Molecular Genetics, vol. 16, no. 22, pp. 2720–2728, 2007. View at Publisher · View at Google Scholar · View at Scopus
  217. C. M. Higgins, C. Jung, and Z. Xu, “ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes,” BMC Neuroscience, vol. 4, no. 1, p. 16, 2003. View at Publisher · View at Google Scholar · View at Scopus
  218. D. Jaarsma, F. Rognoni, W. van Duijn, H. W. Verspaget, E. D. Haasdijk, and J. C. Holstege, “CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations,” Acta Neuropathologica, vol. 102, no. 4, pp. 293–305, 2001. View at Google Scholar
  219. J. Liu, C. Lillo, P. A. Jonsson et al., “Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria,” Neuron, vol. 43, no. 1, pp. 5–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  220. A. Israelson, N. Arbel, S. da Cruz et al., “Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS,” Neuron, vol. 67, no. 4, pp. 575–587, 2010. View at Publisher · View at Google Scholar · View at Scopus
  221. P. Pasinelli, M. E. Belford, N. Lennon et al., “Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria,” Neuron, vol. 43, no. 1, pp. 19–30, 2004. View at Publisher · View at Google Scholar · View at Scopus
  222. S. Pedrini, D. Sau, S. Guareschi et al., “ALS-linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl-2,” Human Molecular Genetics, vol. 19, no. 15, pp. 2974–2986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  223. W. Tan, N. Naniche, A. Bogush, S. Pedrini, D. Trotti, and P. Pasinelli, “Small peptides against the mutant SOD1/Bcl-2 toxic mitochondrial complex restore mitochondrial function and cell viability in mutant SOD1-mediated ALS,” Journal of Neuroscience, vol. 33, no. 28, pp. 11588–11598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  224. T. Nakaya and M. Maragkakis, “Amyotrophic lateral sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity,” Scientific Reports, vol. 8, no. 1, article 15575, 2018. View at Publisher · View at Google Scholar · View at Scopus
  225. W. Wang, L. Wang, J. Lu et al., “The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity,” Nature Medicine, vol. 22, no. 8, pp. 869–878, 2016. View at Publisher · View at Google Scholar · View at Scopus
  226. S. Bannwarth, S. Ait-el-Mkadem, A. Chaussenot et al., “A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement,” Brain, vol. 137, no. 8, pp. 2329–2345, 2014. View at Publisher · View at Google Scholar · View at Scopus
  227. E. C. Genin, M. Plutino, S. Bannwarth et al., “CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis,” EMBO Molecular Medicine, vol. 8, no. 1, pp. 58–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  228. S. C. Barber and P. J. Shaw, “Oxidative stress in ALS: key role in motor neuron injury and therapeutic target,” Free Radical Biology and Medicine, vol. 48, no. 5, pp. 629–641, 2010. View at Publisher · View at Google Scholar · View at Scopus
  229. F. O. Walker, “Huntington’s disease,” The Lancet, vol. 369, no. 9557, pp. 218–228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  230. G. P. Bates, R. Dorsey, J. F. Gusella et al., “Huntington disease,” Nature Reviews Disease Primers, vol. 1, article 15005, 2015. View at Publisher · View at Google Scholar · View at Scopus
  231. M. Gu, M. T. Gash, V. M. Mann, F. Javoy-Agid, J. M. Cooper, and A. H. V. Schapira, “Mitochondrial defect in Huntington’s disease caudate nucleus,” Annals of Neurology, vol. 39, no. 3, pp. 385–389, 1996. View at Publisher · View at Google Scholar · View at Scopus
  232. T. Milakovic and G. V. W. Johnson, “Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin,” Journal of Biological Chemistry, vol. 280, no. 35, pp. 30773–30782, 2005. View at Publisher · View at Google Scholar · View at Scopus
  233. E. Brouillet, P. Hantraye, R. J. Ferrante et al., “Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 15, pp. 7105–7109, 1995. View at Publisher · View at Google Scholar · View at Scopus
  234. J. G. Greene, R. H. P. Porter, R. V. Eller, and J. T. Greenamyre, “Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum,” Journal of Neurochemistry, vol. 61, no. 3, pp. 1151–1154, 1993. View at Publisher · View at Google Scholar · View at Scopus
  235. M. F. Beal, B. T. Hyman, and W. Koroshetz, “Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?” Trends in Neurosciences, vol. 16, no. 4, pp. 125–131, 1993. View at Publisher · View at Google Scholar · View at Scopus
  236. A. Benchoua, Y. Trioulier, D. Zala et al., “Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin,” Molecular Biology of the Cell, vol. 17, no. 4, pp. 1652–1663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  237. A. V. Panov, C. A. Gutekunst, B. R. Leavitt et al., “Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines,” Nature Neuroscience, vol. 5, no. 8, pp. 731–736, 2002. View at Publisher · View at Google Scholar · View at Scopus
  238. Y. S. Choo, G. V. Johnson, M. MacDonald, P. J. Detloff, and M. Lesort, “Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release,” Human Molecular Genetics, vol. 13, no. 14, pp. 1407–1420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  239. R. Luthi-Carter and J.-H. J. Cha, “Mechanisms of transcriptional dysregulation in Huntington’s disease,” Clinical Neuroscience Research, vol. 3, no. 3, pp. 165–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  240. J. Yu, L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein, “PUMA induces the rapid apoptosis of colorectal cancer cells,” Molecular Cell, vol. 7, no. 3, pp. 673–682, 2001. View at Publisher · View at Google Scholar · View at Scopus
  241. J. E. Chipuk, T. Kuwana, L. Bouchier-Hayes et al., “Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis,” Science, vol. 303, no. 5660, pp. 1010–1014, 2004. View at Publisher · View at Google Scholar · View at Scopus
  242. B. I. Bae, H. Xu, S. Igarashi et al., “p53 mediates cellular dysfunction and behavioral abnormalities in Huntington’s disease,” Neuron, vol. 47, no. 1, pp. 29–41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  243. A. Siddiqui, S. Rivera-Sánchez, M. . R. Castro et al., “Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington’s disease,” Free Radical Biology and Medicine, vol. 53, no. 7, pp. 1478–1488, 2012. View at Publisher · View at Google Scholar · View at Scopus
  244. L. Cui, H. Jeong, F. Borovecki, C. N. Parkhurst, N. Tanese, and D. Krainc, “Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration,” Cell, vol. 127, no. 1, pp. 59–69, 2006. View at Publisher · View at Google Scholar · View at Scopus
  245. P. Weydt, V. V. Pineda, A. E. Torrence et al., “Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1α in Huntington’s disease neurodegeneration,” Cell Metabolism, vol. 4, no. 5, pp. 349–362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  246. J. Lin, P. H. Wu, P. T. Tarr et al., “Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice,” Cell, vol. 119, no. 1, pp. 121–135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  247. V. Costa, M. Giacomello, R. Hudec et al., “Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli,” EMBO Molecular Medicine, vol. 2, no. 12, pp. 490–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  248. W. Song, J. Chen, A. Petrilli et al., “Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity,” Nature Medicine, vol. 17, no. 3, pp. 377–382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  249. C.-R. Chang and C. Blackstone, “Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1,” Annals of the New York Academy of Sciences, vol. 1201, no. 1, pp. 34–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  250. J. Kim, J. P. Moody, C. K. Edgerly et al., “Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease,” Human Molecular Genetics, vol. 19, no. 20, pp. 3919–3935, 2010. View at Publisher · View at Google Scholar · View at Scopus
  251. U. Shirendeb, A. P. Reddy, M. Manczak et al., “Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage,” Human Molecular Genetics, vol. 20, no. 7, pp. 1438–1455, 2011. View at Publisher · View at Google Scholar · View at Scopus
  252. U. P. Shirendeb, M. J. Calkins, M. Manczak et al., “Mutant huntingtin’s interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington’s disease,” Human Molecular Genetics, vol. 21, no. 2, pp. 406–420, 2012. View at Publisher · View at Google Scholar · View at Scopus
  253. Y. C. Wong and E. L. F. Holzbaur, “The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation,” Journal of Neuroscience, vol. 34, no. 4, pp. 1293–1305, 2014. View at Publisher · View at Google Scholar · View at Scopus
  254. B. Khalil, N. El Fissi, A. Aouane, M. J. Cabirol-Pol, T. Rival, and J. C. Liévens, “PINK1-induced mitophagy promotes neuroprotection in Huntington’s disease,” Cell Death & Disease, vol. 6, no. 1, article e1617, 2015. View at Publisher · View at Google Scholar · View at Scopus
  255. Y.-N. Rui, Z. Xu, B. Patel et al., “Huntingtin functions as a scaffold for selective macroautophagy,” Nature Cell Biology, vol. 17, no. 3, pp. 262–275, 2015. View at Publisher · View at Google Scholar · View at Scopus
  256. J. Ochaba, T. Lukacsovich, G. Csikos et al., “Potential function for the huntingtin protein as a scaffold for selective autophagy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. 16889–16894, 2014. View at Publisher · View at Google Scholar · View at Scopus
  257. S. E. Browne and M. F. Beal, “Oxidative damage in Huntington’s disease pathogenesis,” Antioxidants & Redox Signaling, vol. 8, no. 11-12, pp. 2061–2073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  258. M. A. Sorolla, G. Reverter-Branchat, J. Tamarit, I. Ferrer, J. Ros, and E. Cabiscol, “Proteomic and oxidative stress analysis in human brain samples of Huntington disease,” Free Radical Biology and Medicine, vol. 45, no. 5, pp. 667–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  259. M. J. Calkins, R. J. Jakel, D. A. Johnson, K. Chan, Y. W. Kan, and J. A. Johnson, “Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 1, pp. 244–249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  260. Y. N. Jin, Y. V. Yu, S. Gundemir et al., “Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin,” PLoS One, vol. 8, no. 3, article e57932, 2013. View at Publisher · View at Google Scholar · View at Scopus
  261. A. S. Tsvetkov, M. Arrasate, S. Barmada et al., “Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration,” Nature Chemical Biology, vol. 9, no. 9, pp. 586–592, 2013. View at Publisher · View at Google Scholar · View at Scopus
  262. L. Quinti, S. Dayalan Naidu, U. Träger et al., “KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 23, pp. E4676–E4685, 2017. View at Publisher · View at Google Scholar · View at Scopus
  263. C. Stack, D. Ho, E. Wille et al., “Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease,” Free Radical Biology and Medicine, vol. 49, no. 2, pp. 147–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  264. V. Campuzano, L. Montermini, M. D. Molto et al., “Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion,” Science, vol. 271, no. 5254, pp. 1423–1427, 1996. View at Publisher · View at Google Scholar · View at Scopus
  265. G. Alper and V. Narayanan, “Friedreich’s ataxia,” Pediatric Neurology, vol. 28, no. 5, pp. 335–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  266. N. Sakamoto, K. Ohshima, L. Montermini, M. Pandolfo, and R. D. Wells, “Sticky DNA, a self-associated complex formed at long GAA·TTC repeats in intron 1 of the frataxin gene, inhibits transcription,” Journal of Biological Chemistry, vol. 276, no. 29, pp. 27171–27177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  267. V. Campuzano, L. Montermini, Y. Lutz et al., “Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes,” Human Molecular Genetics, vol. 6, no. 11, pp. 1771–1780, 1997. View at Publisher · View at Google Scholar · View at Scopus
  268. A. Dürr, M. Cossee, Y. Agid et al., “Clinical and genetic abnormalities in patients with Friedreich’s ataxia,” New England Journal of Medicine, vol. 335, no. 16, pp. 1169–1175, 1996. View at Publisher · View at Google Scholar · View at Scopus
  269. A. H. Koeppen, “Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics,” Journal of the Neurological Sciences, vol. 303, no. 1-2, pp. 1–12, 2011. View at Publisher · View at Google Scholar · View at Scopus
  270. M. L.-H. Huang, E. M. Becker, M. Whitnall, Y. S. Rahmanto, P. Ponka, and D. R. Richardson, “Elucidation of the mechanism of mitochondrial iron loading in Friedreich’s ataxia by analysis of a mouse mutant,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 38, pp. 16381–16386, 2009. View at Publisher · View at Google Scholar · View at Scopus
  271. A. Anzovino, S. Chiang, B. E. Brown, C. L. Hawkins, D. R. Richardson, and M. L. H. Huang, “Molecular alterations in a mouse cardiac model of Friedreich ataxia: an impaired Nrf2 response mediated via upregulation of Keap1 and activation of the Gsk3β axis,” The American Journal of Pathology, vol. 187, no. 12, pp. 2858–2875, 2017. View at Publisher · View at Google Scholar · View at Scopus
  272. M. Whitnall, Y. S. Rahmanto, R. Sutak et al., “The MCK mouse heart model of Friedreich’s ataxia: alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 28, pp. 9757–9762, 2008. View at Publisher · View at Google Scholar · View at Scopus
  273. E. Becker and D. R. Richardson, “Frataxin: its role in iron metabolism and the pathogenesis of Friedreich’s ataxia,” The International Journal of Biochemistry & Cell Biology, vol. 33, no. 1, pp. 1–10, 2001. View at Publisher · View at Google Scholar · View at Scopus
  274. J. M. Cooper and A. H. V. Schapira, “Friedreich’s ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy,” BioFactors, vol. 18, no. 1-4, pp. 163–171, 2003. View at Publisher · View at Google Scholar · View at Scopus
  275. N. Boddaert, K. H. le Quan Sang, A. Rotig et al., “Selective iron chelation in Friedreich ataxia: biologic and clinical implications,” Blood, vol. 110, no. 1, pp. 401–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  276. M. M. Heidari, M. Houshmand, S. Hosseinkhani, S. Nafissi, and M. Khatami, “Complex I and ATP content deficiency in lymphocytes from Friedreich’s ataxia,” Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, vol. 36, no. 01, pp. 26–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
  277. S. Chiang, Z. Kovacevic, S. Sahni et al., “Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich’s ataxia,” Clinical Science, vol. 130, no. 11, pp. 853–870, 2016. View at Publisher · View at Google Scholar · View at Scopus
  278. M. Whitnall, Y. S. Rahmanto, M. L.-H. Huang et al., “Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 50, pp. 20590–20595, 2012. View at Publisher · View at Google Scholar · View at Scopus
  279. G. M. Palomo, T. Cerrato, R. Gargini, and J. Diaz-Nido, “Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-like cells,” Human Molecular Genetics, vol. 20, no. 14, pp. 2807–2822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  280. M. L.-H. Huang, S. Sivagurunathan, S. Ting et al., “Molecular and functional alterations in a mouse cardiac model of Friedreich ataxia: activation of the integrated stress response, eIF2α phosphorylation, and the induction of downstream targets,” The American Journal of Pathology, vol. 183, no. 3, pp. 745–757, 2013. View at Publisher · View at Google Scholar · View at Scopus
  281. J. Skoda, K. Borankova, P. J. Jansson, M. L. H. Huang, R. Veselska, and D. R. Richardson, “Pharmacological targeting of mitochondria in cancer stem cells: an ancient organelle at the crossroad of novel anti-cancer therapies,” Pharmacological Research, vol. 139, pp. 298–313, 2019. View at Publisher · View at Google Scholar
  282. Y. Luo, A. Hoffer, B. Hoffer, and X. Qi, “Mitochondria: a therapeutic target for Parkinson’s disease?” International Journal of Molecular Sciences, vol. 16, no. 9, pp. 20704–20730, 2015. View at Publisher · View at Google Scholar · View at Scopus
  283. S. Cardoso, R. M. Seiça, and P. I. Moreira, “Mitochondria as a target for neuroprotection: implications for Alzheimer’s disease,” Expert Review of Neurotherapeutics, vol. 17, no. 1, pp. 77–91, 2017. View at Publisher · View at Google Scholar · View at Scopus
  284. J. Ruszkiewicz and J. Albrecht, “Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders,” Neurochemistry International, vol. 88, pp. 66–72, 2015. View at Publisher · View at Google Scholar · View at Scopus
  285. Q. Ma, “Role of nrf2 in oxidative stress and toxicity,” Annual Review of Pharmacology and Toxicology, vol. 53, no. 1, pp. 401–426, 2013. View at Publisher · View at Google Scholar · View at Scopus
  286. R. Abeti, A. Baccaro, N. Esteras, and P. Giunti, “Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich’s ataxia models,” Frontiers in Cellular Neuroscience, vol. 12, p. 188, 2018. View at Publisher · View at Google Scholar · View at Scopus
  287. D. M. Miller, I. N. Singh, J. A. Wang, and E. D. Hall, “Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo,” Free Radical Biology and Medicine, vol. 57, pp. 1–9, 2013. View at Publisher · View at Google Scholar · View at Scopus
  288. Y. Liu, J. Yan, C. Sun et al., “Ameliorating mitochondrial dysfunction restores carbon ion-induced cognitive deficits via co-activation of NRF2 and PINK1 signaling pathway,” Redox Biology, vol. 17, pp. 143–157, 2018. View at Publisher · View at Google Scholar · View at Scopus
  289. A. Naskar, V. Prabhakar, R. Singh, D. Dutta, and K. P. Mohanakumar, “Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice,” Journal of Pineal Research, vol. 58, no. 3, pp. 262–274, 2015. View at Publisher · View at Google Scholar · View at Scopus
  290. S. A. Rosales-Corral, D. Acuña-Castroviejo, A. Coto-Montes et al., “Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin,” Journal of Pineal Research, vol. 52, no. 2, pp. 167–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  291. Z. Wang, C. Ma, C. J. Meng et al., “Melatonin activates the Nrf2-ARE pathway when it protects against early brain injury in a subarachnoid hemorrhage model,” Journal of Pineal Research, vol. 53, no. 2, pp. 129–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  292. E. Parada, I. Buendia, R. León et al., “Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression,” Journal of Pineal Research, vol. 56, no. 2, pp. 204–212, 2014. View at Publisher · View at Google Scholar · View at Scopus
  293. S. A. Shah, M. Khan, M. H. Jo, M. G. Jo, F. U. Amin, and M. O. Kim, “Melatonin stimulates the SIRT1/Nrf2 signaling pathway counteracting lipopolysaccharide (LPS)-induced oxidative stress to rescue postnatal rat brain,” CNS Neuroscience & Therapeutics, vol. 23, no. 1, pp. 33–44, 2017. View at Publisher · View at Google Scholar · View at Scopus
  294. H. Murata, H. Takamatsu, S. Liu, K. Kataoka, N. H. Huh, and M. Sakaguchi, “NRF2 regulates PINK1 expression under oxidative stress conditions,” PLoS One, vol. 10, no. 11, article e0142438, 2015. View at Publisher · View at Google Scholar · View at Scopus
  295. A. P. Gureev and V. N. Popov, “Nrf2/ARE pathway as a therapeutic target for the treatment of Parkinson diseases,” Neurochemical Research, pp. 1–7, 2019. View at Publisher · View at Google Scholar
  296. R. K. Chaturvedi and M. Flint Beal, “Mitochondrial diseases of the brain,” Free Radical Biology and Medicine, vol. 63, pp. 1–29, 2013. View at Publisher · View at Google Scholar · View at Scopus
  297. X. Zhang, J. Wu, Y. Dou et al., “Asiatic acid protects primary neurons against C2-ceramide-induced apoptosis,” European Journal of Pharmacology, vol. 679, no. 1-3, pp. 51–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  298. H. Ding, Y. Xiong, J. Sun, C. Chen, J. Gao, and H. Xu, “Asiatic acid prevents oxidative stress and apoptosis by inhibiting the translocation of α-synuclein into mitochondria,” Frontiers in Neuroscience, vol. 12, p. 431, 2018. View at Publisher · View at Google Scholar
  299. H. Jiang, J. Wang, J. Rogers, and J. Xie, “Brain iron metabolism dysfunction in Parkinson’s disease,” Molecular Neurobiology, vol. 54, no. 4, pp. 3078–3101, 2017. View at Publisher · View at Google Scholar · View at Scopus
  300. D. Devos, C. Moreau, J. C. Devedjian et al., “Targeting chelatable iron as a therapeutic modality in Parkinson’s disease,” Antioxidants & Redox Signaling, vol. 21, no. 2, pp. 195–210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  301. R. J. Ward, D. T. Dexter, and R. R. Crichton, “Neurodegenerative diseases and therapeutic strategies using iron chelators,” Journal of Trace Elements in Medicine and Biology, vol. 31, pp. 267–273, 2015. View at Publisher · View at Google Scholar · View at Scopus
  302. P. Dusek, S. A. Schneider, and J. Aaseth, “Iron chelation in the treatment of neurodegenerative diseases,” Journal of Trace Elements in Medicine and Biology, vol. 38, pp. 81–92, 2016. View at Publisher · View at Google Scholar · View at Scopus
  303. J. L. Liu, Y. G. Fan, Z. S. Yang, Z. Y. Wang, and C. Guo, “Iron and Alzheimer’s disease: from pathogenesis to therapeutic implications,” Frontiers in Neuroscience, vol. 12, p. 632, 2018. View at Publisher · View at Google Scholar · View at Scopus
  304. N. P. Mena, O. García-Beltrán, F. Lourido et al., “The novel mitochondrial iron chelator 5-((methylamino)methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death,” Biochemical and Biophysical Research Communications, vol. 463, no. 4, pp. 787–792, 2015. View at Publisher · View at Google Scholar · View at Scopus
  305. Z. H. Shi, G. Nie, X. L. Duan et al., “Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine–induced dopaminergic cell damage: implication for neuroprotection in Parkinson’s disease,” Antioxidants & Redox Signaling, vol. 13, no. 6, pp. 783–796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  306. L. Lannfelt, K. Blennow, H. Zetterberg et al., “Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial,” The Lancet Neurology, vol. 7, no. 9, pp. 779–786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  307. H. M. Schipper, “Heme oxygenase expression in human central nervous system disorders,” Free Radical Biology and Medicine, vol. 37, no. 12, pp. 1995–2011, 2004. View at Publisher · View at Google Scholar · View at Scopus
  308. L. Song, W. Song, and H. M. Schipper, “Astroglia overexpressing heme oxygenase-1 predispose co-cultured PC12 cells to oxidative injury,” Journal of Neuroscience Research, vol. 85, no. 10, pp. 2186–2195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  309. D. R. Richardson, D. J. R. Lane, E. M. Becker et al., “Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 24, pp. 10775–10782, 2010. View at Publisher · View at Google Scholar · View at Scopus
  310. M. L. H. Huang, D. J. R. Lane, and D. R. Richardson, “Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease,” Antioxidants & Redox Signaling, vol. 15, no. 12, pp. 3003–3019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  311. D. R. Richardson and P. Ponka, “Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease,” Journal of Laboratory and Clinical Medicine, vol. 131, no. 4, pp. 306–315, 1998. View at Publisher · View at Google Scholar
  312. D. R. Richardson, C. Mouralian, P. Ponka, and E. Becker, “Development of potential iron chelators for the treatment of Friedreich’s ataxia: ligands that mobilize mitochondrial iron,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1536, no. 2-3, pp. 133–140, 2001. View at Publisher · View at Google Scholar · View at Scopus
  313. P. Ponka, A. Wilczynska, and H. M. Schulman, “Iron utilization in rabbit reticulocytes: a study using succinylacetone as an inhibitor of heme synthesis,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 720, no. 1, pp. 96–105, 1982. View at Publisher · View at Google Scholar · View at Scopus
  314. E. Becker and D. R. Richardson, “Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs,” The Journal of Laboratory and Clinical Medicine, vol. 134, no. 5, pp. 510–521, 1999. View at Publisher · View at Google Scholar · View at Scopus
  315. C. K. Lim, D. S. Kalinowski, and D. R. Richardson, “Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich’s ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class,” Molecular Pharmacology, vol. 74, no. 1, pp. 225–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  316. D. R. Richardson, “The therapeutic potential of iron chelators,” Expert Opinion on Investigational Drugs, vol. 8, no. 12, pp. 2141–2158, 1999. View at Publisher · View at Google Scholar · View at Scopus
  317. A. H. Koeppen, J. A. Morral, A. N. Davis et al., “The dorsal root ganglion in Friedreich’s ataxia,” Acta Neuropathologica, vol. 118, no. 6, pp. 763–776, 2009. View at Publisher · View at Google Scholar · View at Scopus
  318. A. H. Koeppen, R. L. Ramirez, A. B. Becker, and J. E. Mazurkiewicz, “Dorsal root ganglia in Friedreich ataxia: satellite cell proliferation and inflammation,” Acta Neuropathologica Communications, vol. 4, no. 1, p. 46, 2016. View at Publisher · View at Google Scholar · View at Scopus